Currently ongoing is a study (NCT03585764) that is recruiting those with persistent and pretreated high grade serious ovarian cancer (HGSOC) to receive FRα CAR-T cells via the intraperitoneal route and with or without LD chemotherapy. Here, FOLR1 is linked to ovarian cancer.